Advertisement

Search Results

Advertisement



Your search for ,foR matches 32806 pages

Showing 8051 - 8100


covid-19

Oncology Care Remains Under Strain in the Ongoing COVID-19 Pandemic

The resurging COVID-19 pandemic has reawakened challenges for patients and physicians—ones we all hoped were over—and presented stressful situations for patients and providers. Hospitals in some states, particularly those with lower vaccination rates, have faced levels of urgent illness that have...

lung cancer
immunotherapy

Expert Point of View: Ichiro Yoshino, MD, PhD

Ichiro Yoshino, MD, PhD, Professor and Chairman of the Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, Japan, reviewed the finer details of the IMpower010 exploratory analysis.1 He maintained that atezolizumab’s benefit does, indeed, seem to favor some patient...

lung cancer
immunotherapy

IMpower010: Benefits Observed With Atezolizumab Regardless of Stage, Type of Prior Treatment

In an exploratory analysis of the pivotal phase III IMpower010 trial in stage II–IIIA non–small cell lung cancer (NSCLC), continued treatment with the monoclonal antibody atezolizumab after surgery and chemotherapy improved disease-free survival regardless of the type of surgery or chemotherapy...

breast cancer
immunotherapy

Expert Point of View: Shanu Modi, MD

Shanu Modi, MD, of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, called the DESTINY-Breast03 results,1 which showed a highly significant benefit for fam-trastuzumab deruxtecan-nxki (T-DXd) over trastuzumab emtansine (T-DM1), “unprecedented.” She suggested they...

breast cancer
immunotherapy

DESTINY Breast03 Trial Supports Second-Line Use of T-DXd in Metastatic HER2-Positive Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) may become a new option as a second-line treatment of patients with HER2-positive unresectable or metastatic breast cancer, based on results from the global phase III DESTINY-Breast03 trial. These findings were presented by Javier...

Lung Cancer Data From the ESMO Congress 2021

This week, we’re hearing about lung cancer data from the ESMO Congress 2021—specifically, a novel tyrosine kinase inhibitor for HER2 exon 20–mutated non–small cell lung cancer, and a second-line vaccine for HLA-A2–positive disease.

issues in oncology
palliative care

Divya Gupta, MD, on Improving Advance Care Planning Conversations With Patients

Divya Gupta, MD, of the Stanford Cancer Center, discusses an intervention utilizing a computer model and lay care coaches to improve advance care planning conversations with patients who have metastatic cancer. The study, Dr. Gupta reports, showed a trend toward less intensive care for patients at...

skin cancer
gynecologic cancers
prostate cancer
breast cancer
solid tumors
hepatobiliary cancer
gastroesophageal cancer
immunotherapy

FDA Pipeline: Recent Reviews, Designations, Applications, and Authorizations in the Oncology Space

Over the past month, the U.S. Food and Drug Administration (FDA) issued several regulatory decisions for novel treatments for patients with cancer. Priority Review for Relatlimab and Nivolumab Fixed-Dose Combination in Unresectable or Metastatic Melanoma The FDA accepted for Priority Review the...

breast cancer

Effect of Chronic Stress on Treatment Completion and Survival Outcomes in Patients With Breast Cancer

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node–positive or high-risk lymph node–negative HER2-negative breast cancer, according to results presented by Samilia Obeng-Gyasi, MD, MPH, at the 14th ...

prostate cancer

ARAMIS Analysis: Darolutamide Shows Similar Benefits for Black Patients as Observed in the Overall Population

Black patients with prostate cancer who were treated with the androgen receptor inhibitor darolutamide had clinical outcomes similar to those observed in the overall clinical trial population, according to results from the phase III ARAMIS trial presented by Neal Shore, MD, at the 14th AACR...

head and neck cancer

Study Finds Significant Variation in the Incidence of Nasopharyngeal Cancer Among Ethnic Subgroups of Asian Americans

Although nasopharyngeal cancer is quite rare in most parts of the world, including the United States, the cancer causes a significant health burden among Asian Americans, which is a fast-growing but understudied racial group. According to the results from a study by Lee et al presented at the...

Francis S. Collins, MD, PhD, to Step Down as Director of the National Institutes of Health

On October 5, Francis S. Collins, MD, PhD, announced his decision to end his tenure as Director of the National Institutes of Health (NIH) by the end of the year. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years....

gastrointestinal cancer
covid-19

Rates of Diagnosis of Gastrointestinal Cancers—and Stage at Diagnosis—Before and During the COVID-19 Pandemic in Japan

In a study reported in JAMA Network Open, Kuzuu et al found that the COVID-19 pandemic in Japan was associated with reduced rates of new diagnoses, as well as reduced rates of diagnosis at earlier stages, for some gastrointestinal cancers. Study Details The retrospective cohort study included data...

Franco M. Muggia, MD, Internationally Regarded Chemotherapy Pioneer, Dies at 85

Today’s life-saving chemotherapeutics originated from the vision and indefatigable work of pioneers in the field whose unwavering vision challenged the status quo. One such pioneer was Franco M. Muggia, MD, who, in a career lasting more than 50 years, had a hand in the development of some of the...

PALB2 Added to Secondary Findings List

“It is important to note that a paper on managing individuals with germline variants in PALB2 was published in the same issue of Genetics in Medicine as an article on reporting secondary findings in clinical exome and genome sequencing,”1,2 Douglas R. Stewart, MD, told The ASCO Post. “PALB2 is a...

genomics/genetics

Enhanced Surveillance and Risk-Reducing Intervention Options for Individuals With PALB2 Variants

PALB2 germline pathogenic variants are associated with a substantially increased risk for breast cancer and a smaller increased risk for pancreatic and ovarian cancers, warranting enhanced surveillance and the option of risk-reducing interventions, according to a global team of cancer genetic...

Overcoming the Stigma of Small Cell Lung Cancer

Since my small cell lung cancer diagnosis in 2010, I’ve had to overcome not just the distress of having a life-threatening disease, but the stigma attached to it as well. I admit that I was a smoker. I was attracted to smoking when I was 16 and saw how “cool” people looked smoking in television and ...

supportive care

A Guide to End-of-Life Care by a Veteran in Hospice

Given that death is a certain outcome in life, we seek the best way out as possible. What is a good death? According to Jeff Spiess, MD, author of the book Dying With Ease: A Compassionate Guide to Making Wiser End-of-Life Decisions, a good death is one in which pain and suffering are minimized and ...

Glancing Back and Looking Forward in the Fight Against Cancer

“I vividly remember watching television with my older sister, Suzy, and marveling at President Nixon’s signing of the National Cancer Act in December 1971, and thinking ‘for me, this was like a man going to the moon,’” writes Nancy G. Brinker in the foreword to the recently published Centers of the ...

issues in oncology

How ASCO Is Expanding Its Commitment to Diversity and Equity in Cancer Care

Ensuring equitable cancer care for every patient, everywhere has been embedded into ASCO’s mission statement since the Society’s inception nearly 60 years ago. Nevertheless, events of the past year, including the ongoing COVID-19 pandemic, which has disproportionally impacted minority communities, ...

pancreatic cancer

Study Finds Some Pancreatic Cancer Trial Eligibility Criteria Disproportionately Exclude Black Patients

Although lack of clinical trial participation is associated with worse survival outcomes in some malignancies, data show that Black patients with cancer represent just 7.3% of participants—and only 4.5% for such cancers as multiple myeloma—in cancer clinical trials, compared with 84.2% for White...

Expert Point of View: Johnie Rose, MD, PhD

Invited study discussant, Johnie Rose, MD, PhD, called the correlation between Medicaid expansion and changes in 30-day mortality a critical research question. Dr. Rose is Assistant Professor in the Center for Community Health Integration at Case Western Reserve University School of Medicine and...

lung cancer

Study Finds Medicaid Expansion May Be Associated With Decrease in Early Lung Cancer Mortality

Medicare expansion under the Affordable Care Act may have improved outcomes for patients with lung cancer, the leading cause of cancer death in the United States, according to data presented at the 2021 ASCO Quality Care Symposium.1 The National Cancer Database analysis of nearly 12,000 patients...

Donations to St. Jude Children’s Research Center Soar; Inspiration4 SpaceX Journey Exceeds $200 Million Goal

On September 15, 2021, SpaceX launched the Inspiration4 mission, sending four civilians on a 3-day trip orbiting the earth. The passengers were the first to travel on an all-civilian space journey in an effort to further scientific and aerospace research while at the same time raise funds for...

genomics/genetics

FDA Recognizes Memorial Sloan Kettering Database of Molecular Tumor Marker Information

On October 7, the U.S. Food and Drug Administration (FDA) granted recognition to a partial listing of the Memorial Sloan Kettering Cancer Center Oncology Knowledge Base (OncoKB) as the first tumor mutation database to be included in the Public Human Genetic Variant Databases.  The FDA recognized a...

covid-19

Resurgence of COVID-19 Infection in a Large Highly Vaccinated U.S. Health System Workforce

In a letter to the editor in The New England Journal of Medicine, Jocelyn Keehner, MD, of the University of California San Diego Health (UCSDH), and colleagues describe a marked resurgence of COVID-19 infections among fully vaccinated workers in the UCSDH workforce in July 2021.1 The resurgence...

neuroendocrine tumors

Second Primary Cancers in Patients With Neuroendocrine Tumors

In a population-based study reported in a research letter in JAMA Oncology, Bateni et al found that 8% of patients with neuroendocrine tumors (NETs) developed second primary cancers over approximately 7.5 years of follow-up, with types of secondary malignancies differing according to NET type. The...

solid tumors
hematologic malignancies
covid-19

Antibody Response to COVID-19 Vaccination in Patients With Hematologic or Solid Cancers

In a study reported in JAMA Oncology, Mair et al found that antibody response to COVID-19 vaccination was poorer in patients with hematologic or solid malignancies compared with health-care workers. The investigators also identified factors associated with poorer antibody response among patients....

issues in oncology
palliative care

Disparities in Terminal Hospitalization Among Adults With Metastatic Cancer

In a retrospective population-based study reported in JAMA Network Open, Deeb et al found that patients with metastatic cancer from racial and ethnic minority groups and those without private insurance were more likely to be admitted from the emergency department, receive invasive mechanical...

hematologic malignancies

Zanubrutinib for Waldenström’s Macroglobulinemia

On August 31, 2021, the Bruton’s tyrosine kinase inhibitor zanubrutinib was approved for treatment of adults with Waldenström’s macroglobulinemia.1 Supporting Efficacy Data Approval was based on findings in patients receiving zanubrutinib in the phase III open-label ASPEN trial (ClinicalTrials.gov...

President Biden Appoints Members to National Cancer Advisory Board

President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. President Biden...

issues in oncology
survivorship

Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence

Courtney Williams, DrPH, of the National Cancer Institute, discusses the costs associated with cancer survivors who don’t take their medications and cites the need for research to better understand whether residing in an urban or rural area may affect prescription adherence, and what interventions...

lung cancer
immunotherapy

Jyoti Patel, MD, Offers Thoughts on Maintenance Durvalumab Utilization

Study discussant Jyoti Patel, MD, Medical Director of Thoracic Oncology and Assistant Director for Clinical Research at the Lurie Cancer Center of Northwestern University, Chicago, called the research “important for many reasons.” Although the study analyzed data from both open and closed claims,...

lung cancer
immunotherapy

Maintenance Durvalumab: Increased Utilization May Improve Outcomes in NSCLC

Maintenance durvalumab, the standard-of-care treatment for patients with unresectable stage III non–small cell lung cancer (NSCLC), remains significantly underutilized, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung...

lymphoma
immunotherapy

Tackling a Growing Need: Options After CAR T-Cell Therapy for Lymphoma

For aggressive B-cell lymphomas, chimeric antigen receptor (CAR) T-cell therapy saves lives, but relapse remains common, and a second-line standard of care is lacking. During the 2021 Pan Pacific Lymphoma Conference, Grzegorz (Greg) S. Nowakowski, MD, Professor of Medicine and Oncology, Lymphoma...

gynecologic cancers
issues in oncology

Study Examines Benefits of Cervical Cancer Screening Program Tailored to Transgender Men and Nonbinary People

Worldwide, cervical cancer is the fifth most commonly occurring cancer in women, mostly due to human papillomavirus (HPV) infection. In 2020, globally, an estimated 604,237 women were diagnosed with cervical cancer and about 341,843 died from the disease. In the United States, in 2021, it is...

lung cancer
immunotherapy

Black Patients With Advanced NSCLC Receiving Immunotherapy May Have a Lower Risk of Death Than White Patients

Collectively, Black Americans have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers; Black men also have the highest cancer incidence rate. Despite improvements in survival disparities between Black and White Americans in specific cancers ...

hepatobiliary cancer

Addition of Ramucirumab or Merestinib to First-Line Chemotherapy in Advanced Biliary Tract Cancer

In a phase II trial reported in The Lancet Oncology, Juan W. Valle, MD, and colleagues found that no progression-free survival benefit was achieved with the addition of either the VEGFR2 inhibitor ramucirumab or the MEK inhibitor merestinib to first-line cisplatin/gemcitabine chemotherapy in...

head and neck cancer
cns cancers

Factors Associated With Risk of Hearing Loss in Pediatric Patients Receiving Radiation and Chemotherapy

In a single-institution cohort study reported in the Journal of Clinical Oncology, Keilty et al identified factors associated with an increased risk of hearing loss in pediatric patients receiving radiation therapy and chemotherapy for central nervous system and head and neck tumors. The study...

issues in oncology

Benjamin W. Corn, MD, on Integrating Hope Into Clinical Oncology

Benjamin W. Corn, MD, of Shaare Zedek Medical Center in Jerusalem, discusses hope: what it takes for hope to thrive; how he and his colleagues are helping patients and providers become more hopeful through workshops; and his collaboration with the Southwest Oncology Group to aid patients, through...

Emily K. Bergsland, MD: Specializing in Neuroendocrine Tumors, With a Broad Focus on Collaborative Research

Gastrointestinal oncologist Emily K. Bergsland, MD, was born and spent her formative years in La Crosse, Wisconsin, situated on the banks of the Mississippi River. “No one in my family was in the medical field; however, both my parents valued higher education. In fact, when I was in high school, my ...

prostate cancer

Adding Value to Clinical Decision-Making in Nonmetastatic Castration-Resistant Prostate Cancer

Several recent investigations have led to the U.S. Food and Drug Administration (FDA) approval of novel antiandrogens to treat nonmetastatic castration-resistant prostate cancer. Yet, this work has not addressed the treatment of nonmetastatic hormone-sensitive biochemically recurrent prostate...

lymphoma

DA-EPOCH-R for Children and Adolescents With Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

In a phase II trial reported in the Journal of Clinical Oncology, Burke et al found that dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) did not improve event-free survival vs historical controls in children and adolescents with ...

geriatric oncology
symptom management

Effect of Geriatric Assessment–Driven Intervention on Incidence of Severe Chemotherapy-Related Toxicity in Older Patients With Cancer

In a single-center study reported in JAMA Oncology, Daneng Li, MD, and colleagues found that a geriatric assessment–driven intervention (GAIN) was associated with a reduced incidence of grade ≥ 3 adverse events and a higher frequency of completion of advance directives vs standard of care among...

kidney cancer
immunotherapy

Rates of Postprotocol Immunotherapy Use in Patients Enrolled in Kidney Cancer Clinical Trials

In an analysis reported in JAMA Network Open, Sharp et al identified the frequency of use of postprotocol PD-1/PD-L1 inhibitors in control group patients receiving the tyrosine kinase inhibitor sunitinib in randomized trials comparing PD-1/PD-L1 inhibitor–containing combination therapy vs sunitinib ...

colorectal cancer

Does a Longer Interval Before Surgery Among Patients With Locally Advanced Rectal Cancer Lead to Worse Survival?

In an Italian retrospective cohort study reported in JAMA Surgery, Deidda et al found that a longer vs shorter delay to surgery among patients with locally advanced rectal cancer with minor or no pathologic response to neoadjuvant chemoradiotherapy was associated with significantly poorer overall...

lung cancer
immunotherapy

Adjuvant Atezolizumab Following Adjuvant Chemotherapy for Resected Stage IB to IIIA NSCLC

In the phase III IMpower010 trial reported in The Lancet, Enriqueta Felip, MD, and colleagues found that the use of adjuvant atezolizumab after adjuvant platinum-based chemotherapy significantly improved disease-free survival vs best supportive care in patients with resected stage II to IIIA...

hematologic malignancies
leukemia
immunotherapy
global cancer care

A Look at Tomorrow’s CAR T-Cell Therapy Today

Some of the most impressive data on chimeric antigen receptor (CAR) T-cell therapy have come from studies conducted in China. Attendees at the 2021 Pan Pacific Lymphoma Conference heard from one of the leading Chinese investigators, Peihua (Peggy) Lu, MD, of Lu Daopei Hospital, who described the...

breast cancer
issues in oncology

Factors Associated With Early Discontinuation of Endocrine Therapy for Ductal Carcinoma in Situ

In an analysis from the NRG Oncology/NSABP B-35 trial reported in the Journal of Clinical Oncology, N. Lynn Henry, MD, PhD, and colleagues identified toxicity and patient-reported outcome factors associated with early discontinuation of adjuvant endocrine therapy in women with ductal carcinoma in...

gynecologic cancers

Trends in Use of Neoadjuvant Chemotherapy and Association With Overall Survival in Patients With Advanced Ovarian Cancer

In a study reported in JAMA Oncology, Alexander Melamed, MD, MPH, and colleagues found that improvements in median overall survival have been similar in patients from U.S. cancer programs that did vs did not increase their use of neoadjuvant chemotherapy for women with advanced ovarian cancer in...

Advertisement

Advertisement




Advertisement